Impact of antipsychotic medication on the cost of schizophrenia

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 1, 2005, Pages 39-57

  Kilian, Reinhold ^a   Becker, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Antipsychotics; Cost; Medication; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AKATHISIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSENSUS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL LITERATURE; METHODOLOGY; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZATION; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIMULATION; STANDARDIZATION; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 17844380484     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.1.39     Document Type: Review

References (144)

1. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry 47, 833-843 (2002).
2. an der Heiden W, Häfner H. The epidemiology of onset and course of schizophrenia. Eur. Arch. Pychiatr. Clin. Neurosci. 250, 292-303 (2000).
3. Häfner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur. Arch. Pychiatr. Clin. Neurosci. 249, IV/14-IV/26 (1999).
4. Häfner H, an der Heiden W. Evaluating effectiveness and cost of community care for schizophrenic patients. Schizophr. Bull. 17, 441-451 (1991).
5. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158(4), 518-526 (2001).
6. Bagnall A-M, Jones L, Ginelly L, Lewis R, Glanville J, Gilbody S. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assess. 7(13), 1-193 (2003).
7. Glazer WG, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J. Clin. Psychiatry 58(Suppl. 10), 50-54 (1997).
8. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr. Res. 35, S101-S109 (1999).
9. Basu A. Cost-effectiveness analysis of pharmacological treatment in schizophrenia: critical review of results and methodological issues. Schizophr. Res. 71, 445-462 (2004).
10. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 36, 18-26 (2003).
11. Hudson TJ, Sullivan G, Feng W, Owen RR, Thrush CR. Economic evaluations of novel antipsychotic medications: a literature review. Schizophr. Res. 60, 199-218 (2003).
12. Revicki DA. Cost effectiveness of newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr. Opin. Investig. Drugs 2, 110-117 (2001).
13. Sevy S, Visweswaraiah H, Mentschel C, Leucht S, Schooler NR. Relationships between costs and Symptoms in schizophrenia patients treated with antipsychotic medication: a review. J. Clin. Psychiatry 65, 756-765 (2004).
14. Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia. PharmacoEconomics 22 1-8 (2004).
15. Sturm R. The myth of medical cost offset. Psychiatr. Serv. 52, 738-740 (2001).
16. Briggs AH, O'Brien B. The death of cost-minimization analysis? Health Econ. 10, 179-184 (2001).
17. Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision making on the cost-effectiveness plane. Health Econ. 10, 675-680 (2001).
18. Morton V, Torgerson, DJ. Effect of regression to the mean on decision making in health care. Br. Med. J. 326, 1083-1084 (2003).
19. Rice DP. The economic impact of schizophrenia. J. Clin. Psychiatry 60(Suppl. 1), 4-6 (1999).
20. Knapp M. Costs of schizophrenia. Br. J. Psychiatry 171, 509-518 (1997).
21. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A. Comparing pattern and costs of schizophrenia care in five European countries: The EPSILON study. Acta Psychiatr. Scand. 105, 42-54 (2002).
22. Kilian R, Matschinger H, Becker T, Angermeyer MC. A longitudinal analysis of the impact of social an clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatr. Scand. 107, 351-360 (2003).
23. Salize HJ, Rössler W, The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br. J. Psychiatry 169, 42-48 (1996).
24. Haro JM, Salvador-Carulla L, Cabases J, Madoz V, Vázquez-Barquero JL and the PSICOST Group. Utilisation of mental health services and costs of patients with schizophrenia in three areas of spain. Br. J. Psychiatry 173, 334-340 (1998).
25. Amaddeo F, Beecham J, Bonizzato P, Fenyo A, Tansella M, Knapp M. The cost of community-based psychiatric care for first-ever patients. A case register study. Psychol. Med. 28, 173-183 (1998).
26. Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. J. Clin. Psychiatry 60, 14-19 (1999).
27. Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Pol. 51, 1-18 (2000).
28. Dixon L, Lyles A, Smith C, Hoch JS, Fahey M, Postrado L. Use and costs of ambulatory care services among medicare enrollees with schizophrenia. Psychiatr. Serv. 52(6), 786-792 (2001).
29. Byford S, Barber JA, Fiander M, Marshall S, Green J. Factors that influence the costs of caring for patients with severe psychotic illness. Br. J. Psychiatry 178, 441-447 (2001).
30. Crown Wh, Neslusan C, Russo PA, Holzer S, Ozminkowski T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Admin. Pol. Ment. Health. 28, 335-351 (2001).
31. Garattini L, Rossi C, Tediosi F, Cornaggia C, Covelli G, Barbui C. Direct costs of schizophrenia in Italian community psychiatric services. PharmacoEconomics 19, 1217-1225 (2001).
32. Bartels SJ, Clark RE, Peacockm WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am. J. Geriatric Psychiatr. 11, 648-657 (2003).
33. Carr VJ, Halpin SA, Homnes S, Lewin TJ. Costs of schizophrenia and other psychosis in urban australia: findings from the low prevalence (psychotic) disorders study. Aust. NZ J. Psychiatry 37, 31-40 (2003).
34. Häfner H, an der Heiden W. Effectiveness and cost of community care for schizophrenic patients. Hosp. Commun. Psychiatr. 40, 59-63 (1989).
35. Knapp M, Novick D, Genkeer L, Curran CM, McDaid D, on behalf of the SOHO Study Group. Financing health care in Europe: Context for the schizophrenia outpatient health outcomes study. Acta Psychiatr. Scand. 107(Suppl. 416), 30-40 (2003).
36. Knapp M, Beecham J. Costing mental health services. Psychol. Med. 20, 893-908 (1990).
37. Rothbard AB, Kuno E, Schinnar AP, Hadley TR, Turk R. Service utilization and cost of community care for discharged state hospital patients: a 3-year fiAlow-up study. Am. J. Psychiatry 156, 920-927 (1999).
38. Rosenheck R, Perlick D, Bingham S, Liu Mares W, Collins J, Warren S. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 290, 2693-2702 (2003).
39. DeHert M, Thys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L. Health care expenditure on schizophrenia patients in Belgium. Schizophr. Bull. 24, 519-527 (1998).
40. Evers S, Ament A. Costs of schizophrenia in The Netherlands. Schizophr. Bull. 21, 141-153 (1995).
41. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin. Therapeutics 19, 1470-1495 (1997).
42. Lecomte P, De Hert M, van Dijk M, Nuijten M, Nuyts G, Persson U. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 3, 1-11 (2000).
43. Knapp M, Beecham J. Reduced list costings: examniation of an informed short cut in mental health research. Health Econ. 2, 313-322 (1993).
44. DeHert M, Thys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L. Health care expenditure on schizophrenia patients in Belgium. Schizophr. Bull. 24, 519-527 (1998).
45. Bonizzato P, Bisoffi G, Amaddeo F, Chisholm D, Tansella M. Community-based mental health care: to what extent are service costs associated with clinical, social and service history variables? Psychol. Med. 30, 1205-1215 (2000).
46. Bradley CM, Miller LS. Expenditures for treating schizophrenia: a population-based study of Georgia medicaid rcipients. Schizophr. Bull. 24, 479-488 (1998).
47. Kilian R, Roick C, Matschinger H, Bernert S, Mory C, Angermeyer MC. Die Analyse von Kostenstrukturen im Bereich der Schizophreniebehandlung mit einem standardisierten Instrumentarium. (The analysis of cost structures of the treatment of schizophrenia by means of standardized assessment instruments). Psychiat. Prax. 28(Sonderheft 2), S102-S108 (2001).
48. Chandler D, Hu T-W, Meisel J, McGowen M, Madison K. Mental health costs, other public costs, and family buren among mental health clients in capitated integrated service agencies. J. Mental Health Admin. 24, 178-188 (1997).
49. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population based observational study. Br. J. Clin. Pharmacol. 56, 569-575 (2003).
50. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust. NZ J. Psych. 37, 55-61 (2003).
51. Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration - New York Metropolitan region. Schizophr. Bull. 28, 31-42 (2002).
52. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr. Bull. 28, 75-84 (2002).
53. Centrorrino F, Eakin M, Kelleher JP, Goren J, Salvatore P, Egli S. Inpatient antipsychotic drug use in 1998, 1993 and 1989. Am. J. Psychiatry 159, 1932-1935 (2002).
54. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr. Res. 47, 281-292 (2001).
55. Roick C, Kilian R, Angermeyer MC. Indirect costs of schizophrenia. An investigation of the elements and claculation methods for illness related resources-loss. In: Public Health Research and Practice: Report of the Public Health Research Association Saxony 2000-2001. Merker N, Göpfert P, Kirch W, Regensburg S (Eds). Roderer Verlag, Germany, 191-210 (2001).
56. Guest JF, Cookson RF. Cost of schizophrenia to UK society. An incidence based cost-of-illness model for the first five years following diagnosis. PharmacoEconomics 15, 597-610 (1999).
57. Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature ortality: a comparison of the human capital and friction-cost methods for schizophrenia. Can. J. Psychiatry 44, 455-463 (1999).
58. Carr VJ, Lewin TJ, Neil AL, Halpin SA, Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychosis. Br. J. Psychiatry 184, 517-525 (2004).
59. Laugharne R, Byford S, Barber JA, Burns T, Walsh E, Marshall S. The effect of alcohol consumption on cost of care in severe psychotic illness: a report from the UK700 study. Acta Psychiatr. Scand. 106(3), 241-246 (2002).
60. Clouth J, Uber A, Schulenburg JGvd. Kosten der Schizophrenie. Strukturgelichungsmodelle als Instrument der Entscheidugshilfe bei gesundheitsökonomischen Fragestellungen. (Costs of schizophrenia-structural equation models as decision making support tool in health economics). Ges Ökon Qual. Manag. 8, 120-124 (2003).
61. Knapp M, Chisholm D, Astin J, Lelliott P, Audini B. The cost consequences of changing the hospital-community balance: the mental health residential care study. Psychol. Med. 27, 681-692 (1997).
62. Almond S, Knapp M, Fancois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry 184, 346-351 (2004).
63. Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary prctice in Italy. J. Clin. Psychiatry 64, 1293-1299 (2003).
64. Knapp M. Making music of the noise - the cost function approach to evaluation. Br. J. Psychiatry 173(Suppl. 36), 7-11 (1998).
65. Kilian R, Matschinger H, Löffler W, Roick C, Angermeyer MC. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. J. Ment. Health Policy Econ. 5, 21-31 (2002).
66. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Am. Rev. Pub. Health 20, 125-144 (1999).
67. Dunn G, Mirandola M, Amaddeo F, Tansella M. Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br. J. Psychiatry 183, 398-404 (2003).
68. Duan N. Smearing estimate: a nonparametric retransformation method. JASA 78(383), 605-610 (1983).
69. Manning WG. The logged dependent variable, heteroscedasticity and the retransformation problem. J. Health Econ. 17, 283-293 (1998).
70. Drummond MF, Knapp MRJ, Burns TP, Miller KD, Shadwell P. Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study. J. Men. Health Policy Econ. 1, 15-22 (1998).
71. Lyu RR, McCombs JS, Johnstone BM, Muse DN. Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Finance Rev. 23, 83-99 (2001).
72. Foster RH, Goa KL. Risperidone. A pharmaeconomic review of its use in schizophrenia. PharmacoEconomics 14, 97-133 (1998).
73. Foster RH, Goa KL. Olanzapine. A pharmaeconomic review of its use in schizophrenia. PharmacoEconomics 15, 611-640 (1999).
74. Edgell ET, Andersen SW, Johnstone BM, Dulisse BK, Revicki DA, Breier A. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. PharmacoEconomics 18, 567-579 (2000).
75. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch. Gen. Psych. 57, 987-994 (2000).
76. Jerrell J. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr. Bull. 28, 589-605 (2002).
77. Nicholls CJ, Hale AS, Freemantle N. Cost-effectiveness of amusulpride compared with risperidone in patients with schizophrenia. J. Drug Assess. 6, 79-89 (2003).
78. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 337(12), 809 (1997).
79. Slade M, Priebe S. Are randomized controlled trials the only gold that glitters? Br. J. Psychiatry 179, 286-287 (2001).
80. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the department of veterans affairs. Med. Care 39, 302-308 (2001).
81. Sebastian C, Glazer W, Buckley P. Naturalistic studiesof second generation antipsychotics in the treatment of schizophrenia. Curr. Med. Chem. 11(3), 329-342 (2004).
82. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. PharmacoEconomics 15, 423-434 (1999).
83. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic based study. Br. J. Psychiatry 171, 125-130 (1997).
84. Blieden N, Flinders S, Hawkins K, Reid M, Alphs LD, Arfken CL. Health status and health care costs for publicly funded patients with schizophrenia started on clozapine. Psychiatr. Serv. 49, 1590-1593 (1998).
85. Bobes J, Gutiérrez M, Gibert J, González HL, Fernández A. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur. Psychiatr. 13, 158-163 (1998).
86. Cook PE, Goldberg JO, van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community based setting. Can. J. Psychiatry 47, 870-874 (2002).
87. Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. Clinical and economic impat of newer versus older antipsychotic medications in a community mental health center. Clin. Ther. 21, 1105-1116 (1999).
88. Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK. Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatr. Serv. 49, 829-831 (1998).
89. Hammond CM, Pierson JF, Grande TP, Munetz MR, Wilson DR, Pathak DS. Economic evaluation of risperidone in an outpatient population. Ann. Pharmacother. 33, 1160-1166 (1999).
90. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J. Psychopharmacol. 16, 169-175 (2002).
91. Luchins DJ, Hanrahan P, Shinderman M, Lagios L, Fichtner CG. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatr. Serv. 49(8), 1034 (1998).
92. Lynch J, Morrison J, Graves N, Meddis D, Drummond MF, Hellewell JSE. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. Eur. Psychiatr. 16, 307-312 (2001).
93. Lyons C, McDonald P, Maitland JE, Watson JD, King DJ, Mannion MF. Reduction in costs of inpatient stay associated with clozapine treatment. A retrospective study. J. Drug Assess. 1, 1-192 (1998).
94. Rastogi SC, Mynors-Wallis LM. Outcome of clozapine treatment for patients with treatment-resistant schizophrenia in a local clinical service. Psychiatr. Bull. 24, 127-129 (2000).
95. Soholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr. Scand. 107, 344-350 (2003).
96. Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine. Findings from a large US claim database. CNS Drugs 18, 157-164 (2004).
97. Seshamani M. Is clozapine cost-effective. Unanswered issues. Eur. J. Health Econ. 3, S104-S113 (2002).
98. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp. Commun. Psychiatr. 41, 850-854 (1990).
99. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, LeLorier J. Der Einsatz von Risperidon bei schizophrenen Patienten die zuvor mit konventionellen Neuroleptika behandelt wurden reduziert die Inanspruchnahme von Leistungen im Gesundheitswesen. Nervenheilkunde 16, 474-482 (1997).
100. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a medicaid population: traditional agents vs. risperidone. Psychopharmacol. Bull. 34, 373-382 (1998).
101. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr. Serv. 50, 228-232 (1999).
102. Coley KC, Carter CS, DaPos SV, Maxwell RA, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturlisitc setting: a comparison between risperidone, perhenazine, and haloperidol. J. Clin. Psychiatry 60, 850-856 (1999).
103. Sernyak MJ, Rosenheck R, Desai R, Stolar M, Ripper G. Impact of clozapine prescritpion on inpatient resource utilization. J. Nerv. Ment. Dis. 189, 766-773 (2001).
104. Kasper S, Jones M, Duchesne I, on behalf of the RODOS Investigator Group. Risperidone-olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int. Clin. Psychopharm. 16, 189-196 (2001).
105. Fuller MA, Shermock KM, Secic M, Laich JS, Durkin MB. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr. Serv. 53, 855-860 (2002).
106. Gianfrancesco F, Durkin MB, Mahmound R, Wang R-H. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. PharmacoEconomics 20, 413-427 (2002).
107. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, populations-based, mirror immage study. J. Psychopharmacol. 16, 169-175 (2002).
108. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia. A comparison of costs among Texas medicaid recipients. PharmacoEconomics 21, 683-697 (2003).
109. Taylor DM, Wright T, Libretto SE, on behalf of the RODOS Investigator Group. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J. Clin. Psychiatry 64, 589-597 (2003).
110. Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatr. Serv. 54, 742-744 (2003).
111. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 7, 22-34 (2004).
112. Crown WH, Obenchain RL, Englehart L, Lair T, Buesching DP, Croghan T. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat. Med. 17, 1943-1958 (1998).
113. Longford NT. Selection bias and treatment heterogeneity in clinical trials. Stat. Med. 18, 1467-1474 (1999).
114. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J. Clin. Psychiatry 62, 749-756 (2001).
115. Kilian R, Dietrich S, Toumi M, Angermeyer MC. The effects of first generation and second generation antipsychotics on the quality of life of people with schizophrenia in routine outpatient treatment. Acta. Psychiatr. Scand. 110, 108-118 (2004).
116. Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann. Gen. Hospital Psych. 3, 1-11 (2004).
117. Almond S, O'Donnell O. Cost analysis of the threatment of schizophrenia in the UK. A comparison of olanzapine and haloperidol. PharmacoEconomics 13, 575-588 (1998).
118. Byrom BD, Garratt CJ, Kilpatrick AT. Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int. J. Psychiatr. Clin. Practice 2, 129-138 (1998).
119. Davies A, Langly PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clin. Ther. 20, 196-212 (1998).
120. Deckert C, Höffler J, Kortmann J, Linden M, Roth G-D, Struck M. Kostenanalyse der schizophrenie-behandlung in Deutschland. Vergleich von olanzapine, risperidone und haloperidol mit hilfe eines klinischen entscheidungsmodells. Ges. Ökon. Qual. Manag. 6, 161-166 (2001).
121. Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr. Res. 63, 111-119 (2003).
122. Glazer WG, Ereshefsky L. A pharmaeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. J. Clin. Psychiatry 57, 337-345 (1996).
123. Glennie JL. Pharmaeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology overview: pharmaceuticals, Ottawa, Canada (1997).
124. Launois R, Graf von der Schulenburg M, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int. J. Psychiatr. Clin. Prac. 2(Suppl. 2), S79-S86 (1998).
125. Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J. Int. Med. Res. 31, 188-196 (2003).
126. Oh PI, Iskedjian M, Addis A, Lanctòt K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost utility analysis. Can. J. Clin. Pharmacol. 8, 199-206 (2001).
127. Oh PI, Lanctòt K, Mittmann N, Iskedjian M, Einarson TR. Cost-utility of rsiperidone compared with standard conventional antipsychotics in chronic schizophrenia. J. Drug Assess. 5, 39-58 (2002).
128. Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch. Med. Res. 33, 572-580 (2002).
129. Tilden D, Aristides M, Meddis D, Burns T. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin. Ther. 24(10), 1648-1667 (2002).
130. Ginsberg G, Shani S, Lev B. Cost-benefit analyis of risperidone and clozapine in the treatment of schizophrenia in Israel. PharmacoEconomics 13, 231-241 (1998).
131. Rosenheck R, Cramer J, Allan E et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch. Gen. Psych. 56, 565-572 (1999).
132. Hamilton SH, Revicki DA, Edgell ET, Genduso LA. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomized clinical trial. PharmacoEconomics 15, 469-480 (1999).
133. D'Agostino RB. Tutorial in biostatistics. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17, 2265-2281 (1998).
134. Kilian R, Angermeyer MC. Der Einfluss der Neuroleptikabehandlung auf die Inzidenz und die Kosten stationärer psychiatrischer Behandlungen Schizophren Erkrankten: Ergebnisse einer prospektiven Beobachtungsstudie. (The impact of antipsychotic med ication on the incidence and the costs of inpatient treatment in people with schizophrenia: Results from a prospective observational study). Psychiat. Prax. 31, 1-9 (2004).
135. Davies L, Lewis S. Antipsychotic medication for people with first episode schizophrenia: an explorative economic analysis of alternative treatment algorithms. Discussion Paper 178. Centre for Health Economics, The University of York, York, UK (2000).
136. Tilden D, Aristides M, Meddis D, Burns T. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin. Ther. 24, 1648-1667 (2003).
137. Marcotte DE, Wilcox-Gök V. Estimatin the employment and earnings costs of mental illness: recent developments in the United States. Soc. Sci. Med. 53, 21-27 (2001).
138. Hoch JS, Briggs AH, Willan R. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics 11, 415-430 (2002).
139. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and fuctioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment in schizophrenia. J. Clin. Psychiatry 60, 38-46 (1999).
140. Obenchain RL, Johnstone BM. Mixed-model imputations of cost data for early discontinuers ftom a randomized clinical trial. Drug Information J. 33, 191-209 (1999).
141. Rosenheck R, Cramer J, Xu W et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Serv. Res. 33, 1237-1261 (1998).
142. Kilian R, Angermeyer MC, Becker T. Methodische Grundlagen naturalistischer Beobachtungsstudien zur ökonomischen Evaluation der Neuroleptikabehandlung bei schizophrenen Erkrankungen. (Methodological issues of naturalistic observational studies on the economic Evaluation of schizophrenia drug treatment). Gesundheitswesen 66(3), 180-185 (2004).
143. Kasper S, Rosillon D, Duchese I, RODOS investigator Group. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int. Clin. Psychopharm. 16, 179-187 (2001).
144. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK PharmacoEconomics 17, 383-389 (2000).